Piramal Pharma Limited (PPLPHARMA) Price & Analysis

Compare

11 Followers

PPLPHARMA Stock Chart & Stats

₹192.65

-₹4.80(-1.92%)

At close: Jan 08 4:00 PM EST

₹192.65

-₹4.80(-1.92%)

Day’s Range― - ―

52-Week Range₹134.70 - ₹241.00

Previous CloseN/A

Volume1.66M

Average Volume (3M)264.14K

Market Cap

₹184.30B

Enterprise Value₹226.87B

Total Cash (Recent Filing)₹7.44B

Total Debt (Recent Filing)₹48.51B

Price to Earnings (P/E)―

Beta0.90

Next Earnings

May 27, 2026

EPS Estimate

0.84

Next Dividend Ex-DateN/A

Dividend Yield0.08%

Share Statistics

EPS (TTM)-0.70

Shares Outstanding1,329,248,200

10 Day Avg. Volume501,791

30 Day Avg. Volume264,138

Financial Highlights & Ratios

PEG Ratio0.84

Price to Book (P/B)3.72

Price to Sales (P/S)3.30

P/FCF Ratio132.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.05

Revenue Forecast (FY)₹90.81B

Bulls Say, Bears Say

Bulls Say

Diversified CDMO And Specialty Pharma ModelPiramal's dual revenue streams—contract development & manufacturing (CDMO) plus specialty pharma—provide durable diversification. CDMO yields long-term supply agreements and milestone fees while specialty products offer branded sales, reducing single-source risk and supporting steady medium-term cash flows.

Healthy Balance Sheet And Manageable LeverageA debt-to-equity of ~0.60 and a solid equity base signal balanced capital structure and financial flexibility. This reduces refinancing risk, supports investment in capacity or regulatory upgrades, and cushions the business against cyclical volatility over the next several months.

High Gross Margin And Improving EBITA robust gross margin (~64.7%) combined with an improving EBIT margin indicates strong pricing power (likely from CDMO services) and better operational control. This margin base supports reinvestment and resilience to input-cost swings over the medium term.

Bears Say

Fluctuating Free Cash FlowSignificant FCF volatility suggests uneven timing of capex or receipts from projects, reducing predictable internal funding. This can force reliance on external financing for growth or working capital, complicating investment plans and increasing financing costs over the next 2–6 months.

Inconsistent Net Profit MarginsVolatile net margins point to sensitivity to project mix, one-offs or pricing pressures that affect bottom-line stability. That inconsistency makes earnings visibility poor, hampers long-term planning, and can limit management's ability to sustainably increase shareholder returns.

Moderate EBITDA Margin Limits Cash GenerationDespite high gross margins, a moderate EBITDA margin implies elevated operating expenses or inefficiencies. This constrains conversion of revenue into repeatable operating cash, limiting capacity to self-fund expansion or buffer downturns across the medium term.

Piramal Pharma Limited News

Piramal Critical Care and Blue-Zone Partner to Recycle Waste Anaesthetic Gases

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an announcement. Piramal Critical Care, Inc. and Canada-based Blue-Zone Technologies...

1M ago

Piramal Pharma to Acquire Kenalog Injectable Portfolio from Bristol-Myers Squibb

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has provided an update. Piramal Pharma’s step-down wholly owned subsidiary, Piramal Critical...

2M ago

Piramal Pharma Strengthens Senior Management, Appoints Interim Company Secretary

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an update. Piramal Pharma Limited has expanded its senior management...

2M ago

Piramal Pharma Posts Higher Profit Despite Softer Revenue in Q3 FY26

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has shared an update. Piramal Pharma Limited’s board has approved the unaudited...

2M ago

Piramal Pharma Posts Muted Q3 FY26 Results but Signals Early Recovery and Continued Expansion

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has provided an update. Piramal Pharma Limited reported a 3% year-on-year decline...

2M ago

Piramal Pharma Reshuffles Senior Management and Appoints Interim Company Secretary

An update from Piramal Pharma Limited ( ($IN:PPLPHARMA) ) is now available. Piramal Pharma Limited’s board has expanded...

2M ago

Piramal Pharma Posts Q3 Loss as CDMO Weakness Weighs, Signals Early Demand Recovery

The latest update is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma reported a weak performance...

2M ago

Piramal Pharma Revamps Senior Management, Appoints New Compliance Chief

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) just unveiled an update. Piramal Pharma Limited has overhauled its senior management...

2M ago

Piramal Pharma Revamps Senior Management and Key Compliance Role

The latest announcement is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma Limited has announced a...

2M ago

Piramal Pharma Shareholders Approve Appointment of Independent Director via Postal Ballot

The latest announcement is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma Limited has announced that...

2M ago

PPLPHARMA FAQ

What was Piramal Pharma Limited’s price range in the past 12 months?

Piramal Pharma Limited lowest stock price was ₹134.70 and its highest was ₹241.00 in the past 12 months.

What is Piramal Pharma Limited’s market cap?

Piramal Pharma Limited’s market cap is ₹184.30B.

When is Piramal Pharma Limited’s upcoming earnings report date?

Piramal Pharma Limited’s upcoming earnings report date is May 27, 2026 which is in 71 days.

How were Piramal Pharma Limited’s earnings last quarter?

Piramal Pharma Limited released its earnings results on Jan 28, 2026. The company reported -₹0.7 earnings per share for the quarter, missing the consensus estimate of -₹0.245 by -₹0.455.

Is Piramal Pharma Limited overvalued?

According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Piramal Pharma Limited pay dividends?

Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here

What is Piramal Pharma Limited’s EPS estimate?

Piramal Pharma Limited’s EPS estimate is 0.84.

How many shares outstanding does Piramal Pharma Limited have?

Piramal Pharma Limited has 1,329,248,200 shares outstanding.

What happened to Piramal Pharma Limited’s price movement after its last earnings report?

Piramal Pharma Limited reported an EPS of -₹0.7 in its last earnings report, missing expectations of -₹0.245. Following the earnings report the stock price went up 1.015%.

Which hedge fund is a major shareholder of Piramal Pharma Limited?

Currently, no hedge funds are holding shares in IN:PPLPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Piramal Pharma Limited

Piramal Pharma Limited (PPLPHARMA) is a leading global pharmaceutical company based in India, operating under the Piramal Group. The company focuses on developing and manufacturing a wide range of pharmaceutical products, including branded and generic formulations, active pharmaceutical ingredients (APIs), and contract development and manufacturing services (CDMO). PPLPHARMA is committed to providing innovative healthcare solutions across various therapeutic areas such as oncology, cardiovascular, and central nervous system disorders, leveraging its extensive research and development capabilities.